

Reference:	FOI.20530.26
Subject:	Immunology medicines
Date of Request:	26 May 2026

Your request and our response

I would be grateful if you could tell me how many patients were treated between January and March 2026 for the list of drugs named in the questions below.

Please fill in the template below with the number of patients or a format of your choice. Please include data for all hospitals in your organisation.

Hywel Dda University Health Board (UHB) is unable to provide you with the exact number of patients for some of the medications due to the low number (less than 5) and have therefore, replaced the figures in the tables with an asterisk (*), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000 (FoIA). This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (UK GDPR) as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

1. How many patients were treated in total regardless of diagnosis with the following drugs between 1st Jan 2026 and 31st March 2026, or the latest 3-month period for which you have data?

The UHB provides within the table below, the number of patients treated with the listed medications, for any condition, during the period 1 February to 30 April 2026, the most recent period the data is available.

Drug Name	<u>Total number of patients treated regardless of diagnosis</u>
Adalimumab	607
Etrasimod	*
Filgotinib	31
Golimumab	24
Guselkumab	*
Infliximab (Biosimilars)	222
Infliximab (Remicade)	*
Mirikizumab	*
Ozanimod	*
Risankizumab	160
Tofacitinib	9
Upadacitinib	127

Ustekinumab	168
Vedolizumab	216

2. How many patients were treated by the Gastroenterology Department or Clinic with the following drugs between 1st Jan 2026 and 31st March 2026, or the latest 3-month period for which you have data?

The UHB provides within the table below, the number of patients treated by the Gastroenterology department, with the listed medications, during the period 1 February to 30 April 2026.

Drug Name	Number of patients treated by the Gastroenterology Department
Adalimumab	151
Etrasimod	*
Filgotinib	12
Golimumab	0
Guselkumab	*
Infliximab (Biosimilars)	103
Infliximab (Remicade)	0
Mirikizumab	*
Ozanimod	*
Risankizumab	101
Tofacitinib	*
Upadacitinib	85
Ustekinumab	124
Vedolizumab	147

3. How many patients with Crohn's Disease or Ulcerative Colitis, in total regardless of department / clinic, were treated with the following drugs between 1st Jan 2026 and 31st March 2026, or the latest 3-month period for which you have data?

The UHB provides within the table below the number of patients diagnosed with Crohn's Disease and Ulcerative Colitis that were treated with the listed medications, during the period 1 February to 30 April 2026.

Drug Name	Number patients with Crohn's Disease	Number patients with Ulcerative Colitis
Adalimumab	135	15
Etrasimod	0	*
Filgotinib	0	10
Golimumab	0	0
Guselkumab	*	0
Infliximab (Biosimilars)	93	64
Infliximab (Remicade)	0	*

Mirikizumab	0	*
Ozanimod	0	*
Risankizumab	90	20
Tofacitinib	0	*
Upadacitinib	26	59
Ustekinumab	80	45
Vedolizumab	63	143